Phase II trial of esorubicin (4′deoxydoxorubicin, DxDx) in patients with small cell lung cancer

James R. Rigas, Mark G. Kris, Richard J. Gralla, Robert T. Heelan, Linda D. Marks

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


Esorubicin (4′-deoxydoxorubicin or DxDx) is an analog of doxorubicin with preclinical antitumor activity and no significant cardiotoxicity in model systems. Eleven patients with small cell lung cancer who had previously received chemotherapy were given esorubicin (25 mg/m2 intravenously) every 3 weeks. No major objective responses were observed (95% confidence limits: 0-25%). Nine of the 11 patients had grade 2 or greater toxicity, with 55% of the patients experiencing grade 3 or greater toxicity [myelosuppression (4/11), anemia (2/11) or elevated liver enzymes (3/11)]. Nausea, vomiting, alopecia and intravenous site phlebitis were also seen. Three of the 11 patients received 3 or more course of esorubicin without evidence of significant cardiotoxicity. At this dose and shedule, no significant antitumor response were seen in this population of patients. Esorubicin, with this low response rate and significant toxicity, appears to be of limited utility in this disease.

Original languageEnglish (US)
Pages (from-to)187-190
Number of pages4
JournalInvestigational New Drugs
Issue number2
StatePublished - May 1991
Externally publishedYes


  • deoxydoxorubicin
  • esorubicin
  • phase II trial
  • small cell lung cancer

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Phase II trial of esorubicin (4′deoxydoxorubicin, DxDx) in patients with small cell lung cancer'. Together they form a unique fingerprint.

Cite this